This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gao, J. Articles by Isaacs, J. T. Search for Related Content PubMed PubMed Citation Articles by Gao, J. Articles by Isaacs, J. T.

Conversion from a Paracrine to an Autocrine Mechanism of Androgen-stimulated Growth during Malignant Transformation of Prostatic Epithelial Cells¹

Johns Hopkins Oncology Center [J. G., J. T. A., J. T. I.]; Graduate Program of Cellular and Molecular Medicine [J. G.]; and James Buchanan Brady Urology Institute, Department of Urology [J. T. I.], The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231

Normal adult prostate epithelium of both human and rat origin was transplanted with Matrigel into intact or androgen-ablated (i.e., castrated) nude mice. Within these transplants, an influx of mouse mesenchymal cells was one of the earliest events to occur resulting in the development of a collar of smooth muscle cells and fibroblasts surrounding the transplanted epithelium. A subset of these surrounding stromal cells express androgen receptor (AR). The surrounded transplanted epithelium initially expresses high molecular weight cytokeratins characteristic of prostatic basal cells and AR. In both intact and androgen-ablated hosts, this epithelium subsequently develops a patent lumen producing a rudimentary glandular acini. Only in the nonablated hosts, however, do these rudimentary acini undergo a further proliferative growth phase, as determined by Ki67 immunocytochemical stainings and the development of a low molecular weight cytokeratin positive layer of luminal (i.e., secretory) epithelial cells. Because AR is expressed in both the donor epithelium and host (i.e., mouse) stromal cells, this androgen-stimulated growth response could involve either autocrine pathways initiated within donor normal adult epithelial cells themselves or paracrine pathways initiated within the AR-expressing subset of mouse stromal cells. To resolve this issue, mice carrying the testicular feminized mutation in the X-linked AR gene were cross-bred to AR-wt nude mice to produce AR-null nude male mice. None of the cells in these AR-null nude male mice express functional AR protein. Therefore, these animals can be used to prevent any possibility of host stromal cell paracrine involvement in initiating an androgen-stimulated growth response when normal adult or malignant prostatic epithelial cells are transplanted into these null hosts. In these AR-null nude male mice, the androgen-stimulated growth of normal adult prostatic epithelial cells did not occur (i.e., androgen-induced growth response of normal prostatic epithelial cells requires stromal cell paracrine involvement). In contrast, using four different prostatic cancer models (i.e., human PC-82, human LNCaP, human LAPC-4, and rat R3327G), the androgen-stimulated growth of prostatic cancer cells occurred identically in both AR-null and AR-wt nude male mice (i.e., a direct autocrine mechanism is responsible for androgen-stimulated growth of malignant prostatic epithelial cells). In summary, a fundamental change in the mechanism for androgen-stimulated growth occurs during the transformation from normal to malignant prostatic epithelial cells.

This article has been cited by other articles:

				Y. Zong, L. Xin, A. S. Goldstein, D. A. Lawson, M. A. Teitell, and O. N. Witte ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells PNAS, July 28, 2009; 106(30): 12465 - 12470. [Abstract] [Full Text] [PDF]

				J. M D'Antonio, D. J Vander Griend, and J. T Isaacs DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer Endocr. Relat. Cancer, June 1, 2009; 16(2): 325 - 332. [Abstract] [Full Text] [PDF]

				D. J. Vander Griend, W. L. Karthaus, S. Dalrymple, A. Meeker, A. M. DeMarzo, and J. T. Isaacs The Role of CD133 in Normal Human Prostate Stem Cells and Malignant Cancer-Initiating Cells Cancer Res., December 1, 2008; 68(23): 9703 - 9711. [Abstract] [Full Text] [PDF]

				H. Wang, D. Sun, P. Ji, J. Mohler, and L. Zhu An AR-Skp2 pathway for proliferation of androgen-dependent prostate-cancer cells J. Cell Sci., August 1, 2008; 121(15): 2578 - 2587. [Abstract] [Full Text] [PDF]

				A. Sharma, C. E.S. Comstock, E. S. Knudsen, K. H. Cao, J. K. Hess-Wilson, L. M. Morey, J. Barrera, and K. E. Knudsen Retinoblastoma Tumor Suppressor Status Is a Critical Determinant of Therapeutic Response in Prostate Cancer Cells Cancer Res., July 1, 2007; 67(13): 6192 - 6203. [Abstract] [Full Text] [PDF]

				A.-M. Moilanen, J. Hakkola, M. H. Vaarala, S. Kauppila, P. Hirvikoski, J. T. Vuoristo, R. J. Edwards, and T. K. Paavonen Characterization of androgen-regulated expression of CYP3A5 in human prostate Carcinogenesis, May 1, 2007; 28(5): 916 - 921. [Abstract] [Full Text] [PDF]

				Q. Ji, L. Chang, F. Z. Stanczyk, M. Ookhtens, A. Sherrod, and A. Stolz Impaired Dihydrotestosterone Catabolism in Human Prostate Cancer: Critical Role of AKR1C2 as a Pre-Receptor Regulator of Androgen Receptor Signaling Cancer Res., February 1, 2007; 67(3): 1361 - 1369. [Abstract] [Full Text] [PDF]

				P. Cano, A. Godoy, R. Escamilla, R. Dhir, and S. A. Onate Stromal-Epithelial Cell Interactions and Androgen Receptor-Coregulator Recruitment Is Altered in the Tissue Microenvironment of Prostate Cancer Cancer Res., January 15, 2007; 67(2): 511 - 519. [Abstract] [Full Text] [PDF]

				P. Hammarsten, S. Halin, P. Wikstom, R. Henriksson, S. H. Rudolfsson, and A. Bergh Inhibitory Effects of Castration in an Orthotopic Model of Androgen-Independent Prostate Cancer Can Be Mimicked and Enhanced by Angiogenesis Inhibition Clin. Cancer Res., December 15, 2006; 12(24): 7431 - 7436. [Abstract] [Full Text] [PDF]

				I. V. Litvinov, D. J. Vander Griend, L. Antony, S. Dalrymple, A. M. De Marzo, C. G. Drake, and J. T. Isaacs Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells PNAS, October 10, 2006; 103(41): 15085 - 15090. [Abstract] [Full Text] [PDF]

				P Singh, A Uzgare, I Litvinov, S R Denmeade, and J T Isaacs Combinatorial androgen receptor targeted therapy for prostate cancer. Endocr. Relat. Cancer, September 1, 2006; 13(3): 653 - 666. [Abstract] [Full Text] [PDF]

				Y. Xu, S. L. Dalrymple, R. E. Becker, S. R. Denmeade, and J. T. Isaacs Pharmacologic Basis for the Enhanced Efficacy of Dutasteride against Prostatic Cancers. Clin. Cancer Res., July 1, 2006; 12(13): 4072 - 4079. [Abstract] [Full Text] [PDF]

				L. Xin, M. A. Teitell, D. A. Lawson, A. Kwon, I. K. Mellinghoff, and O. N. Witte Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor PNAS, May 16, 2006; 103(20): 7789 - 7794. [Abstract] [Full Text] [PDF]

				H. Le, J. T. Arnold, K. K. McFann, and M. R. Blackman DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E952 - E960. [Abstract] [Full Text] [PDF]

				S. Dalrymple, L. Antony, Y. Xu, A. R. Uzgare, J. T. Arnold, J. Savaugeot, L. J. Sokoll, A. M. De Marzo, and J. T. Isaacs Role of Notch-1 and E-Cadherin in the Differential Response to Calcium in Culturing Normal versus Malignant Prostate Cells Cancer Res., October 15, 2005; 65(20): 9269 - 9279. [Abstract] [Full Text] [PDF]

				D M Peehl Primary cell cultures as models of prostate cancer development Endocr. Relat. Cancer, March 1, 2005; 12(1): 19 - 47. [Abstract] [Full Text] [PDF]

				A. R. Uzgare and J. T. Isaacs Enhanced Redundancy in Akt and Mitogen-activated Protein Kinase-induced Survival of Malignant versus Normal Prostate Epithelial Cells Cancer Res., September 1, 2004; 64(17): 6190 - 6199. [Abstract] [Full Text] [PDF]

				C. A. Heinlein and C. Chang Androgen Receptor in Prostate Cancer Endocr. Rev., April 1, 2004; 25(2): 276 - 308. [Abstract] [Full Text] [PDF]

				S. Zha, S. Ferdinandusse, S. Denis, R. J. Wanders, C. M. Ewing, J. Luo, A. M. De Marzo, and W. B. Isaacs {alpha}-Methylacyl-CoA Racemase as an Androgen-Independent Growth Modifier in Prostate Cancer Cancer Res., November 1, 2003; 63(21): 7365 - 7376. [Abstract] [Full Text] [PDF]

				I. V. Litvinov, A. M. De Marzo, and J. T. Isaacs Is the Achilles' Heel for Prostate Cancer Therapy a Gain of Function in Androgen Receptor Signaling? J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 2972 - 2982. [Full Text] [PDF]

				J. A. Tuxhorn, S. J. McAlhany, T. D. Dang, G. E. Ayala, and D. R. Rowley Stromal Cells Promote Angiogenesis and Growth of Human Prostate Tumors in a Differential Reactive Stroma (DRS) Xenograft Model Cancer Res., June 1, 2002; 62(11): 3298 - 3307. [Abstract] [Full Text] [PDF]

				D. C. Whitacre, S. Chauhan, T. Davis, D. Gordon, A. E. Cress, and R. L. Miesfeld Androgen Induction of in Vitro Prostate Cell Differentiation Cell Growth Differ., January 1, 2002; 13(1): 1 - 11. [Abstract] [Full Text] [PDF]